Quantcast
Last updated on April 16, 2014 at 13:23 EDT

Latest Antibody Stories

2013-10-28 08:24:44

BERLIN, DRESDEN and AACHEN, Germany, October 28, 2013 /PRNewswire/ -- Thanks to innovative software, scientific publishers now have the possibility to place advertisements that match the content of their online biomedical publications exactly. Advertisers in the life science sector are able to target their promotions at their potential users. And scientists - the audience of published content - will no longer be annoyed by inappropriate advertisements. This solution was...

2013-10-24 23:25:16

MarketResearchReports.Biz announces addition of new report “Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-and-cells-emerging-opportunities-for-the-biopharmaceutical-industry. Albany, NY (PRWEB) October 24, 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities...

2013-10-17 08:28:49

Expands patent portfolio to broadly protect antibody generation methodologies utilized by AnaptysBio's SHM-XEL platform SAN DIEGO, Oct. 17, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its proprietary ABELmAb((TM)) libraries. Once issued, the allowed claims will broadly protect the...

2013-10-15 16:25:18

SAN FRANCISCO, Oct. 15, 2013 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, presented today the first data involving a dual-warhead antibody drug conjugate (ADC) at the World ADC Summit in San Francisco. Trevor Hallam, Ph.D., chief scientific officer of Sutro, reported the data in a presentation titled "Producing Homogeneous ADCs with Combination Warheads,"...

2013-10-11 23:19:29

Protein Engineering Market report categorizes the market for protein engineering by geography, applications, products and technology. http://www.marketsandmarkets.com/Market-Reports/protein-antibody-engineering-market-898.html (PRWEB) October 11, 2013 The report "Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global...

2013-10-10 04:21:07

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, October 10, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013. The milestone is based on the generation of a stabilised (StaR(R)) form of the first GPCR target selected by MorphoSys, a key step...

2013-10-09 12:26:32

CAMBRIDGE, England, October 9, 2013 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company, announces today it has notified the English Court that it will defend the UK patent proceedings brought by Regeneron in respect of European patent EP1360287. Regeneron initiated these proceedings in September 2013. Kymab will defend the UK patent action on the grounds of non-infringement and invalidity of the patent. Earlier, in June 2013, Kymab opposed the...

2013-10-08 10:38:51

Researchers develop a first-of-its-kind mathematical model for the biological process that keeps your immune system working Scientists at USC have created a mathematical model that explains and predicts the biological process that creates antibody diversity – the phenomenon that keeps us healthy by generating robust immune systems through hypermutation. The work is a collaboration between Myron Goodman, professor of biological sciences and chemistry at the USC Dornsife College of...

2013-10-07 23:00:06

The report “Cancer Monoclonal Antibody Partnering Terms and Agreements” provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. Dallas, Texas (PRWEB) October 08, 2013 The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the world’s leading healthcare companies.     Trends in...

2013-10-01 23:34:38

Precise antibody drug delivery has entered a totally new level where now a potent drug can be positioned within angstroms of its target, decreasing off-target side effects. The first results of an EDC (Extracellular Drug Conjugate) were published showing significant activity against head and neck cancers. Madison, Wisconsin (PRWEB) October 01, 2013 CENTROSE, the leader in EDC Technology, announced the publication of the first EDC scientific article. The article published today in the...